NeuroPace (NASDAQ:NPCE) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

NeuroPace (NASDAQ:NPCE) announced its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The firm had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.14 million.

NeuroPace Stock Down 2.4 %

Shares of NASDAQ:NPCE opened at $11.63 on Thursday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $15.77. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a market cap of $347.13 million, a P/E ratio of -11.63 and a beta of 2.05. The firm has a fifty day moving average price of $12.72 and a 200 day moving average price of $9.76.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martha Morrell sold 3,200 shares of NeuroPace stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the transaction, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,352,479 shares of company stock worth $50,670,217. 22.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Cantor Fitzgerald boosted their price target on shares of NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group assumed coverage on NeuroPace in a report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Wells Fargo & Company lifted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.20.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.